The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
暂无分享,去创建一个
[1] H. Moore,et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. , 2009, Archives of general psychiatry.
[2] Tomiki Sumiyoshi,et al. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression , 1995, Brain Research.
[3] Samuel M. McClure,et al. BOLD Responses Reflecting Dopaminergic Signals in the Human Ventral Tegmental Area , 2008, Science.
[4] M. Laruelle. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[5] D. Sibley,et al. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. , 1982, The Journal of biological chemistry.
[6] M. Laakso,et al. Midbrain dopamine D2/3 receptor binding in schizophrenia , 2006, European Archives of Psychiatry and Clinical Neuroscience.
[7] A. Arnsten,et al. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. , 2007, Cerebral cortex.
[8] M. Laruelle,et al. Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.
[9] R. V. Van Heertum,et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[10] M Laruelle,et al. Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.
[11] J. Lisman. Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia? , 2012, Current Opinion in Neurobiology.
[12] Tyrone D. Cannon,et al. Brain dopamine d1 receptors in twins discordant for schizophrenia. , 2006, The American journal of psychiatry.
[13] D. Doudet,et al. 6-18F-DOPA PET study in patients with schizophrenia , 2000, Psychiatry Research: Neuroimaging.
[14] G. Firnau,et al. [18F]Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine , 1978 .
[15] P Riederer,et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[16] A. Grace,et al. Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia , 2008, Neurotoxicity Research.
[17] T. McGlashan,et al. Striatal Dopamine Synthesis in First-degree Relatives of Patients with Schizophrenia , 2008, Biological Psychiatry.
[18] Harumasa Takano,et al. Regional dopamine synthesis in patients with schizophrenia using L-[β-11C]DOPA PET , 2009, Schizophrenia Research.
[19] M. Laruelle,et al. Striatal and Extrastriatal Dopamine D2/D3 Receptors in Schizophrenia Evaluated With [18F]fallypride Positron Emission Tomography , 2010, Biological Psychiatry.
[20] Christer Halldin,et al. Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography , 2006, Psychiatry Research: Neuroimaging.
[21] Patricia S. Goldman-Rakic,et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.
[22] S. Otsuki,et al. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain , 1986, Biological Psychiatry.
[23] R. V. Van Heertum,et al. Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.
[24] J. M. Ollinger,et al. Positron Emission Tomography , 2018, Handbook of Small Animal Imaging.
[25] P. McGuire,et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. , 2010, Archives of general psychiatry.
[26] M. Laruelle. Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[27] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.
[28] T. Crow,et al. 3H-flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors , 2004, Psychopharmacology.
[29] J. Hietala,et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. , 2000, The American journal of psychiatry.
[30] K. Berridge,et al. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? , 1998, Brain Research Reviews.
[31] R. Narendran,et al. Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: a PET study with [11C]NNC112 , 2012, Journal of psychopharmacology.
[32] A. Deutch. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. , 1992, Journal of neural transmission. Supplementum.
[33] Gary Remington,et al. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.
[34] Christer Halldin,et al. Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.
[35] A Carlsson,et al. Antipsychotic drugs, neurotransmitters, and schizophrenia. , 1978, The American journal of psychiatry.
[36] A. Gjedde,et al. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms , 1998, Synapse.
[37] L. Siever,et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide , 2004, Biological Psychiatry.
[38] H. Möller,et al. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1 , 2005, Journal of psychopharmacology.
[39] Kun-Ju Lin,et al. Dopamine transporter change in drug-naı̈ve schizophrenia: an imaging study with 99mTc-TRODAT-1 , 2003, Schizophrenia Research.
[40] Minda R. Lynch,et al. Schizophrenia and the D1 receptor: Focus on negative symptoms , 1992, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[41] P. Seeman. All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors , 2011, CNS neuroscience & therapeutics.
[42] Sylvain Houle,et al. High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [11C]-(+)-PHNO , 2006, Biological Psychiatry.
[43] S. Kapur,et al. Dopamine, prediction error and associative learning: A model-based account , 2006, Network.
[44] J. Krystal,et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT , 2000, Biological Psychiatry.
[45] E. Kandel,et al. Transient Overexpression of Striatal D2 Receptors Impairs Operant Motivation and Interval Timing , 2007, The Journal of Neuroscience.
[46] D. Weinberger. Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.
[47] M Laruelle,et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.
[48] Harumasa Takano,et al. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. , 2009, Journal of psychiatric research.
[49] R. Conley,et al. Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study , 1998, Molecular Psychiatry.
[50] A. Carlsson. Does dopamine play a role in schizophrenia? , 1977, Psychological Medicine.
[51] R. Gur,et al. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. , 1997, Archives of general psychiatry.
[52] Gavin P. Reynolds,et al. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia , 2002, Schizophrenia Research.
[53] P. McGuire,et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis , 2011, Molecular Psychiatry.
[54] E. Fernandez-Egea,et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait , 2007, Psychopharmacology.
[55] David A Lewis,et al. Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia , 2000, Brain Research Bulletin.
[56] A. Malhotra,et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] Sohee Park,et al. Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. , 2011, The American journal of psychiatry.
[58] S. Kapur,et al. The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.
[59] Alain Dagher,et al. Stress-Induced Dopamine Release in Humans at Risk of Psychosis: a [11C]Raclopride PET Study , 2008, Neuropsychopharmacology.
[60] S. Kapur,et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels , 2000, Psychopharmacology.
[61] D. Copolov,et al. The Binding of Both [3H]Nemonapride and [3H]Raclopride Is Increased in Schizophrenia , 1997, Biological Psychiatry.
[62] S. Kapur,et al. The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence , 2008, Neuropsychopharmacology.
[63] C. Nahmias,et al. Dopamine visualized in the basal ganglia of living man , 1983, Nature.
[64] B. Dawant,et al. Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic Subjects , 2009, Biological Psychiatry.
[65] K. Davis,et al. Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.
[66] J. Hietala,et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.
[67] R. Conley,et al. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. , 1996, Neuroreport.
[68] G. Reynolds,et al. [3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. , 1985, European journal of pharmacology.
[69] M. Hallett,et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA , 2008, Psychiatry Research: Neuroimaging.
[70] D. Javitt,et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia , 2008, Trends in Neurosciences.
[71] Alan A. Wilson,et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study , 2000, Psychopharmacology.
[72] G. Reynolds,et al. Are Striatal Dopamine D4 Receptors Increased in Schizophrenia? , 1994, Journal of neurochemistry.
[73] Mark Slifstein,et al. In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390 , 2007, Molecular Imaging and Biology.
[74] T. Hyde,et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[75] M. Bergström,et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(β-11C) DOPA and PET , 1999, Biological Psychiatry.
[76] S. Haber,et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. , 2010, Archives of general psychiatry.
[77] R. V. Van Heertum,et al. NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans , 2002, Synapse.
[78] Anissa Abi-Dargham,et al. Do we still believe in the dopamine hypothesis? New data bring new evidence. , 2004, The international journal of neuropsychopharmacology.
[79] D. Linszen,et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT , 2001, Schizophrenia Research.
[80] Bradley T. Christian,et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia , 2006, Schizophrenia Research.
[81] Alan A. Wilson,et al. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]‐(+)‐PHNO in rats using an intracerebral beta‐sensitive system , 2006, Synapse.
[82] Status of the dopaminergic system in post-mortem brain in schizophrenia. , 1988, Psychopharmacology bulletin.
[83] A. Grace,et al. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. , 1995, Drug and alcohol dependence.
[84] A. Meyer-Lindenberg,et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia , 2002, Nature Neuroscience.
[85] P. Seeman,et al. Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.
[86] Tyrone D. Cannon,et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. , 2005, Archives of general psychiatry.
[87] Johannes Schwarz,et al. Psychosis pathways converge via D2High dopamine receptors , 2006, Synapse.
[88] Mark Slifstein,et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. , 2005, The American journal of psychiatry.
[89] M. Laruelle,et al. Glutamate, Dopamine, and Schizophrenia , 2003 .
[90] Andrew D. Roberts,et al. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa , 1999, Neurology.
[91] Van Rossum Jm. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. , 1966 .
[92] Ryan D Ward,et al. Impaired timing precision produced by striatal D2 receptor overexpression is mediated by cognitive and motivational deficits. , 2009, Behavioral neuroscience.
[93] C. Crouzel,et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients , 1997, Schizophrenia Research.
[94] R. Murray,et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia , 2011, Psychological Medicine.
[95] P. Goldman-Rakic,et al. Functional and anatomical aspects of prefrontal pathology in schizophrenia. , 1997, Schizophrenia bulletin.
[96] S. Kapur,et al. From dopamine to salience to psychosis—linking biology, pharmacology and phenomenology of psychosis , 2005, Schizophrenia Research.
[97] E. Walker,et al. Dopamine receptors in the brains of schizophrenia patients: a meta‐analysis of the findings , 2001, Behavioural pharmacology.
[98] J. Pavía,et al. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism , 2005, Psychopharmacology.
[99] Henrik Walter,et al. Prediction error as a linear function of reward probability is coded in human nucleus accumbens , 2006, NeuroImage.
[100] Arno Villringer,et al. Dysfunction of ventral striatal reward prediction in schizophrenia , 2006, NeuroImage.
[101] J. Kleinman,et al. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients , 1994, Biological Psychiatry.
[102] Kevin T. Hansen,et al. Dopamine D2 densities and the schizophrenic brain , 1998, Schizophrenia Research.
[103] M. Laruelle,et al. [11C]NNC 112 Selectivity for Dopamine D1 and Serotonin 5-HT2A Receptors: A PET Study in Healthy Human Subjects , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[104] Marc Laruelle,et al. Imaging D2 Receptor Occupancy by Endogenous Dopamine in Humans , 1997, Neuropsychopharmacology.
[105] W. Schultz. Predictive reward signal of dopamine neurons. , 1998, Journal of neurophysiology.
[106] Nikolaos Koutsouleris,et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug–naive schizophrenic patients , 2006, European Archives of Psychiatry and Clinical Neuroscience.
[107] J. Hietala,et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia , 1999, Schizophrenia Research.
[108] J. Tiihonen,et al. Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients , 2003, Molecular Psychiatry.
[109] A. Meyer-Lindenberg,et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. , 2005, Archives of general psychiatry.
[110] Paul J. Harrison. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications , 2004, Psychopharmacology.
[111] M. Laruelle,et al. Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects , 2009, Biological Psychiatry.
[112] J. Kleinman,et al. Dopamine receptor subtype imbalance in schizophrenia. , 1987, Life sciences.
[113] E. Kandel,et al. Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning , 2006, Neuron.
[114] D. Erritzoe,et al. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. , 2003, Neuroimaging clinics of North America.
[115] M. Cannon,et al. Psychotic-like experiences in the general population: characterizing a high-risk group for psychosis , 2010, Psychological Medicine.
[116] A. Grace,et al. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission , 2003, Nature Neuroscience.
[117] Sylvain Houle,et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]‐(+)‐PHNO, a new agonist radiotracer for imaging the high‐affinity state of D2 receptors in vivo using positron emission tomography , 2006, Journal of neurochemistry.
[118] R. Murray,et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study , 2011, Molecular Psychiatry.
[119] P. Glimcher,et al. Midbrain Dopamine Neurons Encode a Quantitative Reward Prediction Error Signal , 2005, Neuron.
[120] P. Sokoloff,et al. The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches , 1995, European Neuropsychopharmacology.
[121] E. Bézard,et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. , 2006, CNS & neurological disorders drug targets.
[122] Marie-Claude Asselin,et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. , 2009, Archives of general psychiatry.
[123] Jeffrey A Lieberman,et al. Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity , 1997, Neuropsychopharmacology.
[124] Eleanor H. Simpson,et al. A Possible Role for the Striatum in the Pathogenesis of the Cognitive Symptoms of Schizophrenia , 2010, Neuron.
[125] C. Halldin,et al. Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. , 2003, The international journal of neuropsychopharmacology.
[126] P Seeman,et al. Dopamine D2 receptors mapped in rat brain with [3H](+)PHNO , 1994, Synapse.
[127] G. Sedvall,et al. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. , 2002, The American journal of psychiatry.
[128] A. Arnsten. Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia , 2011, International Journal of Developmental Neuroscience.
[129] Janet B W Williams,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[130] P. Chen,et al. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. , 2004, The American journal of psychiatry.
[131] A. Grace,et al. The Yin and Yang of dopamine release: a new perspective , 2007, Neuropharmacology.
[132] R. Mizrahi. Advances in PET analyses of stress and dopamine , 2010, Neuropsychopharmacology.
[133] Alan A. Wilson,et al. D2-Receptor Upregulation is Dependent upon Temporal Course of D2-Occupancy: A Longitudinal [11C]-Raclopride PET Study in Cats , 2009, Neuropsychopharmacology.
[134] D. Weinberger,et al. Dopamine, the prefrontal cortex and schizophrenia , 1997, Journal of psychopharmacology.
[135] F. Yasuno,et al. Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. , 2004, The American journal of psychiatry.
[136] S. Tanada,et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. , 2002, Archives of general psychiatry.
[137] Ariel Graff-Guerrero,et al. The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study , 2009, Neuropsychopharmacology.
[138] R. Dolan,et al. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans , 2006, Nature.
[139] A. Grace. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.
[140] P S Goldman-Rakic,et al. The “Psychic” Neuron of the Cerebral Cortex , 1999, Annals of the New York Academy of Sciences.
[141] A. Grace,et al. The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes , 2004, Neuropsychopharmacology.
[142] Philip Seeman,et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[143] Alan C. Evans,et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[144] R. Joosten,et al. Reward-Predictive Cues Enhance Excitatory Synaptic Strength onto Midbrain Dopamine Neurons , 2008, Science.
[145] Karmen K. Yoder,et al. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia , 2004, Schizophrenia Research.
[146] Ariel Graff-Guerrero,et al. Brain region binding of the D2/3 agonist [11C]‐(+)‐PHNO and the D2/3 antagonist [11C]raclopride in healthy humans , 2008, Human brain mapping.
[147] E. Bird,et al. Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia , 1988, Synapse.
[148] J. Pierri,et al. Decreased density of tyrosine hydroxylase–immunoreactive axons in the entorhinal cortex of schizophrenic subjects , 2000, Biological Psychiatry.
[149] C. Svarer,et al. Frontal Dopamine D2/3 Receptor Binding in Drug-Naive First-Episode Schizophrenic Patients Correlates with Positive Psychotic Symptoms and Gender , 2006, Biological Psychiatry.
[150] J. Krystal,et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[151] Marc Laruelle,et al. Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in Schizophrenia , 2003, Neuropsychopharmacology.
[152] D. Charney,et al. Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.
[153] R. Murray,et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. , 2011, The American journal of psychiatry.
[154] A. Lawrence,et al. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. , 2004, Archives of general psychiatry.
[155] S. Snyder,et al. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.
[156] S H Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.
[157] Merja Haaparanta,et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia , 2001, Schizophrenia Research.
[158] J. Krystal,et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.
[159] Anthony A. Grace,et al. Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia , 2012, Neuropharmacology.
[160] Bita Moghaddam,et al. Bringing Order to the Glutamate Chaos in Schizophrenia , 2003, Neuron.
[161] M. Iyo,et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.
[162] S. Kapur,et al. Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[163] H. Möller,et al. Dual-isotope SPECT imaging of striatal dopamine: First episode, drug naïve schizophrenic patients , 2008, Schizophrenia Research.